Seawolf Therapeutics Launches with $100M Funding to Advance DNA Therapeutics
Seawolf Therapeutics has secured $100 million in Series A funding to develop DNA-based drugs using specialized lipid nanoparticles. Major investors include Novartis, Eli Lilly, and CRISPR Therapeutics
cen · 2026-11-17 00:00